- 【Updated on May 12, 2025】 Integration of CiNii Dissertations and CiNii Books into CiNii Research
- Trial version of CiNii Research Knowledge Graph Search feature is available on CiNii Labs
- 【Updated on June 30, 2025】Suspension and deletion of data provided by Nikkei BP
- Regarding the recording of “Research Data” and “Evidence Data”
-
- NAOTA Misaki
- 独立行政法人医薬品医療機器総合機構
-
- FUEKI Osamu
- 独立行政法人医薬品医療機器総合機構
-
- HIRABAYASHI Keiji
- 独立行政法人医薬品医療機器総合機構
-
- NAKAE Dai
- 東京農業大学 応用生物科学部 食品安全健康学科
Bibliographic Information
- Other Title
-
- ICH S9ガイドライン質疑応答集の概要とその作成経緯
- ICH S9 ガイドライン シツギ オウトウシュウ ノ ガイヨウ ト ソノ サクセイ ケイイ
Search this article
Description
<p>ICH S9 guideline provides recommendations for nonclinical evaluations to support the development of anticancer pharmaceuticals in clinical trials for the treatment of patients with advanced disease and limited therapeutic options.“Questions and Answers: Nonclinical Evaluation for Anticancer Pharmaceuticals (ICH S9 Q & As)”has developed to add precise and concrete explanation on issues which have been interpreted differently among regulatory agencies, or between such agencies and sponsors, in the operation of the guideline. In this article, we describe an overview of the ICH S9 Q & As and the process of their development, from the standpoint of regulatory members of the ICH S9 Q & As Implementation Working Group.</p>
Journal
-
- Regulatory Science of Medical Products
-
Regulatory Science of Medical Products 10 (1), 11-14, 2020
Society for Regulatory Science of Medical Products
- Tweet
Details 詳細情報について
-
- CRID
- 1390283659847943680
-
- NII Article ID
- 130007793096
-
- NII Book ID
- AA12678631
-
- ISSN
- 21890447
- 21857113
-
- NDL BIB ID
- 030247792
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
- NDL Search
- CiNii Articles
-
- Abstract License Flag
- Disallowed